000272981 001__ 272981
000272981 005__ 20250127091741.0
000272981 0247_ $$2pmc$$apmc:PMC11671962
000272981 0247_ $$2doi$$a10.1136/jnnp-2024-333413
000272981 0247_ $$2pmid$$apmid:38825349
000272981 0247_ $$2ISSN$$a0022-3050
000272981 0247_ $$2ISSN$$a0266-8637
000272981 0247_ $$2ISSN$$a0368-329X
000272981 0247_ $$2ISSN$$a1468-330X
000272981 0247_ $$2ISSN$$a2753-0477
000272981 0247_ $$2ISSN$$a2753-0485
000272981 0247_ $$2altmetric$$aaltmetric:164109937
000272981 037__ $$aDZNE-2024-01360
000272981 041__ $$aEnglish
000272981 082__ $$a610
000272981 1001_ $$aOlde Heuvel, Florian$$b0
000272981 245__ $$aDynamics of synaptic damage in severe traumatic brain injury revealed by cerebrospinal fluid SNAP-25 and VILIP-1.
000272981 260__ $$aLondon$$bBMJ Publishing Group$$c2024
000272981 3367_ $$2DRIVER$$aarticle
000272981 3367_ $$2DataCite$$aOutput Types/Journal article
000272981 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1733309261_24135
000272981 3367_ $$2BibTeX$$aARTICLE
000272981 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000272981 3367_ $$00$$2EndNote$$aJournal Article
000272981 520__ $$aBiomarkers of neuronal, glial cells and inflammation in traumatic brain injury (TBI) are available but they do not specifically reflect the damage to synapses, which represent the bulk volume of the brain. Experimental models have demonstrated extensive involvement of synapses in acute TBI, but biomarkers of synaptic damage in human patients have not been explored.Single-molecule array assays were used to measure synaptosomal-associated protein-25 (SNAP-25) and visinin-like protein 1 (VILIP-1) (along with neurofilament light chain (NFL), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillar acidic protein (GFAP), interleukin-6 (IL-6) and interleukin-8 (IL-8)) in ventricular cerebrospinal fluid (CSF) samples longitudinally acquired during the intensive care unit (ICU) stay of 42 patients with severe TBI or 22 uninjured controls.CSF levels of SNAP-25 and VILIP-1 are strongly elevated early after severe TBI and decline in the first few days. SNAP-25 and VILIP-1 correlate with inflammatory markers at two distinct timepoints (around D1 and then again at D5) in follow-up. SNAP-25 and VILIP-1 on the day-of-injury have better sensitivity and specificity for unfavourable outcome at 6 months than NFL, UCH-L1 or GFAP. Later elevation of SNAP-25 was associated with poorer outcome.Synaptic damage markers are acutely elevated in severe TBI and predict long-term outcomes, as well as, or better than, markers of neuroaxonal injury. Synaptic damage correlates with initial injury and with a later phase of secondary inflammatory injury.
000272981 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000272981 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x1
000272981 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000272981 650_7 $$2Other$$atraumatic brain injury
000272981 650_7 $$2NLM Chemicals$$aSynaptosomal-Associated Protein 25
000272981 650_7 $$2NLM Chemicals$$aBiomarkers
000272981 650_7 $$2NLM Chemicals$$aNeurocalcin
000272981 650_7 $$2NLM Chemicals$$aneurofilament protein L
000272981 650_7 $$2NLM Chemicals$$aVSNL1 protein, human
000272981 650_7 $$2NLM Chemicals$$aNeurofilament Proteins
000272981 650_7 $$2NLM Chemicals$$aSNAP25 protein, human
000272981 650_7 $$0EC 3.4.19.12$$2NLM Chemicals$$aUbiquitin Thiolesterase
000272981 650_7 $$2NLM Chemicals$$aGlial Fibrillary Acidic Protein
000272981 650_7 $$2NLM Chemicals$$aInterleukin-6
000272981 650_7 $$2NLM Chemicals$$aUCHL1 protein, human
000272981 650_7 $$2NLM Chemicals$$aGFAP protein, human
000272981 650_2 $$2MeSH$$aHumans
000272981 650_2 $$2MeSH$$aBrain Injuries, Traumatic: cerebrospinal fluid
000272981 650_2 $$2MeSH$$aSynaptosomal-Associated Protein 25: cerebrospinal fluid
000272981 650_2 $$2MeSH$$aMale
000272981 650_2 $$2MeSH$$aAdult
000272981 650_2 $$2MeSH$$aFemale
000272981 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000272981 650_2 $$2MeSH$$aMiddle Aged
000272981 650_2 $$2MeSH$$aNeurocalcin: cerebrospinal fluid
000272981 650_2 $$2MeSH$$aSynapses: pathology
000272981 650_2 $$2MeSH$$aNeurofilament Proteins: cerebrospinal fluid
000272981 650_2 $$2MeSH$$aUbiquitin Thiolesterase: cerebrospinal fluid
000272981 650_2 $$2MeSH$$aGlial Fibrillary Acidic Protein: cerebrospinal fluid
000272981 650_2 $$2MeSH$$aInterleukin-6: cerebrospinal fluid
000272981 650_2 $$2MeSH$$aYoung Adult
000272981 650_2 $$2MeSH$$aAged
000272981 7001_ $$aLi, Zhenghui$$b1
000272981 7001_ $$0P:(DE-2719)9002961$$aRiedel, Daniel$$b2$$udzne
000272981 7001_ $$0P:(DE-2719)9002026$$aHalbgebauer, Steffen$$b3$$udzne
000272981 7001_ $$0P:(DE-2719)9001560$$aOeckl, Patrick$$b4$$udzne
000272981 7001_ $$aMayer, Benjamin$$b5
000272981 7001_ $$aGotzman, Nina$$b6
000272981 7001_ $$00000-0002-2525-8775$$aShultz, Sandy$$b7
000272981 7001_ $$aSemple, Bridgette$$b8
000272981 7001_ $$0P:(DE-2719)9002007$$aTumani, Hayrettin$$b9$$udzne
000272981 7001_ $$0P:(DE-2719)2812633$$aLudolph, Albert C$$b10$$udzne
000272981 7001_ $$0P:(DE-2719)2812855$$aBöckers, Tobias$$b11$$udzne
000272981 7001_ $$aMorganti-Kossmann, Cristina$$b12
000272981 7001_ $$00000-0003-4273-4267$$aOtto, Markus$$b13
000272981 7001_ $$0P:(DE-2719)2812851$$aRoselli, Francesco$$b14$$eLast author$$udzne
000272981 773__ $$0PERI:(DE-600)1480429-3$$a10.1136/jnnp-2024-333413$$gVol. 95, no. 12, p. 1158 - 1167$$n12$$p1158 - 1167$$tJournal of neurology, neurosurgery, and psychiatry$$v95$$x0022-3050$$y2024
000272981 8564_ $$uhttps://pub.dzne.de/record/272981/files/DZNE-2024-01360%20SUP.pdf
000272981 8564_ $$uhttps://pub.dzne.de/record/272981/files/DZNE-2024-01360.pdf$$yOpenAccess
000272981 8564_ $$uhttps://pub.dzne.de/record/272981/files/DZNE-2024-01360%20SUP.pdf?subformat=pdfa$$xpdfa
000272981 8564_ $$uhttps://pub.dzne.de/record/272981/files/DZNE-2024-01360.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000272981 909CO $$ooai:pub.dzne.de:272981$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000272981 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002961$$aExternal Institute$$b2$$kExtern
000272981 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002026$$aExternal Institute$$b3$$kExtern
000272981 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001560$$aExternal Institute$$b4$$kExtern
000272981 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002007$$aExternal Institute$$b9$$kExtern
000272981 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812633$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000272981 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2812855$$aExternal Institute$$b11$$kExtern
000272981 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812851$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b14$$kDZNE
000272981 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000272981 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x1
000272981 9141_ $$y2024
000272981 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
000272981 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-24
000272981 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-24
000272981 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-24
000272981 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-24
000272981 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROL NEUROSUR PS : 2022$$d2023-08-24
000272981 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJ NEUROL NEUROSUR PS : 2022$$d2023-08-24
000272981 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-24
000272981 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
000272981 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-24
000272981 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-24
000272981 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-24
000272981 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000272981 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-24
000272981 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2023-08-24$$wger
000272981 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
000272981 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-24
000272981 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-24
000272981 9201_ $$0I:(DE-2719)1910001$$kAG Roselli$$lMetabolic Changes in Neurodegeneration$$x0
000272981 9201_ $$0I:(DE-2719)5000077$$kClinical Study Center (Ulm)$$lClinical Study Center (Ulm)$$x1
000272981 980__ $$ajournal
000272981 980__ $$aVDB
000272981 980__ $$aUNRESTRICTED
000272981 980__ $$aI:(DE-2719)1910001
000272981 980__ $$aI:(DE-2719)5000077
000272981 9801_ $$aFullTexts